Update on new pulmonary therapies

Current Opinion in Pulmonary Medicine

Volumn 15, Issue 6, 2009, Pages 604-610

  Retsch Bogart, George Z ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Airway surface liquid; Antibiotics; Cystic fibrosis; Cystic fibrosis transmembrane conductance regulator; Gene therapy

Indexed keywords

ALPHA 1 ANTITRYPSIN; AMIKACIN; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ARIKACE; AZTREONAM; AZTREONAM LYSINE; CIPROFLOXACIN; COMPOUND 552 02; CORTICOSTEROID; CYTOKINE; DENUFOSOL; FOSFOMYCIN; GS 9411; IBUPROFEN; ION TRANSPORT AFFECTING AGENT; LEVOFLOXACIN; LINEZOLID; MANNITOL; OSMOTIC AGENT; PLACEBO; PTC 124; SODIUM CHANNEL BLOCKING AGENT; SODIUM CHLORIDE; TOBRAMYCIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; VANCOMYCIN; VX 770; VX 809;

ANTIBIOTIC THERAPY; CHLORIDE CONDUCTANCE; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; GENE DELETION; HUMAN; LUNG FIBROSIS; LUNG FUNCTION; LUNG INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MUCOCILIARY CLEARANCE; MULTIPLE CYCLE TREATMENT; NONSENSE MUTATION; OSMOSIS; PATHOPHYSIOLOGY; PSEUDOMONAS INFECTION; QUALITY OF LIFE; REVIEW; SURVIVAL; TREATMENT OUTCOME;

AMINOPHENOLS; AMINOPYRIDINES; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; BENZODIOXOLES; BIOLOGICAL MARKERS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENETIC MARKERS; GENETIC THERAPY; HUMANS; MUTATION; OXADIAZOLES; QUINOLONES; RESPIRATORY SYSTEM AGENTS; SALINE SOLUTION, HYPERTONIC;

EID: 70349835744     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328331805b     Document Type: Review

References (51)

1. Moss RB, Milla C, Columbo J, et al. Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2b trial. Hum Gene Ther 2007; 18:726-732.
2. Hyde SC, Pringle IA, Abdullah S, et al. CpG plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat Biotechnol 2008; 26:549-551.
3. Griesenbach U, Alton EWFW, on behalf of the UK Cystic Fibrosis Gene Therapy Consortium. Gene transfer to the lung: lessons learned from more than 2 decades of CF gene therapy. Adv Drug Deliv Rev 2009; 61:128-129.
4. Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008; 372:719-727.
5. A phase 3 efficacy and safety study of PTC124 as an oral treatment for nonsense-mutation-mediated cystic fibrosis. http://clinicaltrials.gov/ct2/ show/NCT00803205.
6. Vertex. Press Release October 20, 2008. Vertex website [online]. http:// investors.vrtx.com/releasedetail.cfm?ReleaseID=341350.
7. Study of VX-770 in cystic fibrosis subjects age 12 and older with the G551D mutationVX770. http://clinicaltrials.gov/ct2/show/NCT00909532
8. Study of VX-770 in cystic fibrosis subjects age 6 to 11 with the G551D mutation. http://clinicaltrials.gov/ct2/show/NCT00909727
9. Study of VX-809 in cystic fibrosis subjects with the DF508-CFTR gene mutation. http://clinicaltrials.gov/ct2/show/NCT00865904
10. Clunes MT, Boucher RC. Cystic fibrosis: the mechanisms of pathogenesis of an inherited lung disorder. Drug Discov Today Dis Mech 2007; 4:63-72.
11. Sagel S, Gibson R, Emerson J, et al. Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J Pediatr 2009; 154:183-188.
12. Linnane BM, Hall GL, Nolan G, et al. Lung function in infants with cystic fibrosis diagnosed by newborn screening. Am J Respir Crit Care Med 2008; 178:1238-1244.
13. Sly PD, Brennan S, Gangell C, et al. on behalf of AREST for Cystic Fibrosis (AREST-CF). Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. Am J Respir Crit Care Med 2009; 180:146-152.
14. Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006; 354:241-250.
15. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006; 354:229-240.
16. Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic Fibrosis Foundation, Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176:957-969.
17. Subbarao P, Balkovec S, Solomon M, Ratjen F. Pilot study of safety and tolerability of inhaled hypertonic saline in infants with cystic fibrosis. Pediatr Pulmonol 2007; 42:417-476.
18. Dellon EP, Donaldson SH, Johnson R, Davis SD. Safety and tolerability of inhaled hypertonic saline in young children with cystic fibrosis. Pediatr Pulmonol 2008; 43:1100-1106.
19. Infant Study of Inhaled Saline (ISIS) in cystic fibrosis. http://clinicaltrials.gov/ ct2/show/NCT00709280
20. Jaques A, Daviskas E, Turton JA, et al. Inhaled mannitol improves lung function in cystic fibrosis. Chest 2008; 133:1388-1396.
21. Minasian C, Wallis C, Metcalfe C, Bush A. Bronchial provocation testing with dry powder mannitol in children with cystic fibrosis. Pediatr Pulmonol 2008; 43:1078-1084.
22. Moss RB, Anbar R, Wilmott R, et al. Phase 3 study of denufosol tetrasodium for the treatment of cystic fibrosis. Am J Respir Crit Care Med 2009; 179:A1189. Inspire website [online]. http://www.inspirepharm.com/r-and- d/publications.php.
23. TIGER-2 study of denufosol tetrasodium inhalation solution in patients with cystic fibrosis (CF) lung disease. http://clinicaltrials.gov/ct2/show/ NCT00625612.
24. Burrows E, Southern KW, Noone P. Sodium channel blockers for cystic fibrosis. Cochrane Database Syst Rev 2006:3CD005087.
25. Zhou Z, Treis D, Schubert SC, et al. Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in bENaC-overexpressing mice. Am J Respir Crit Care Med 2008; 178:1245-1256.
26. Mall MA, Harkema JR, Trojanek JB, et al. Development of chronic bronchitis and emphysema in b-epithelial Na+ channel-overexpressing mice. Am J Respir Crit Care Med 2008; 177:730-742.
27. Trial to assess the safety, tolerability and pharmacokinetics of GS-9411 in healthy male volunteers. http://clinicaltrials.gov/ct2/show/NCT00800579.
28. Hirsh AJ, Zhang J, Zamurs A, et al. Pharmacological properties of 552-02, a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease. J Pharmacol Exper Ther 2008; 325:77-88.
29. Nichols DP, Konstan MW, Chmiel JF. Anti-inflammatory therapies for cystic fibrosis-related lung disease. Clin Rev Allergy Immunol 2008; 35:135-153.
30. Griese M, Kappler M, Gaggar A, Hartl D. Inhibition of airway proteases in cystic fibrosis lung disease. Eur Respir J 2008; 32:783-795.
31. Griese M, Latzin P, Kappler M, et al. a1-Antitypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J 2007; 29:240-250.
32. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995; 332:848-854.
33. Lands LC, Milner R, Cantin AM, et al. High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr 2007; 151:249-254.
34. Konstan MW, Schluchter MD, Xue W, Davis PB. Clinical use of ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 2007; 176:1084-1089.
35. Lands LC, Stanojevic S. Oral nonsteroidal anti-inflammatory drug therapy for cystic fibrosis (review). Cochrane Database Syst Rev 2007:CD001505.
36. Valerius NH, KochC,Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonization in cystic fibrosis by early treatment. Lancet 1991; 338:725-726.
37. Tacetti G, Campana S, Festini F, et al. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 2005; 26:458-461.
38. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1998; 23:330-335.
39. Ratjen F, Munck A, Kho P. Short and long-term efficacy of inhaled tobramycin in early P. aeruginosa infection: the ELITE study [abstract #334]. Pediatr Pulmonol 2008; 43 (Suppl 31):319.
40. Treggiari MM, Rosenfeld M, Mayer-Hamblett N, et al., EPIC Study Group. Early antipseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study. Contemp Clin Trials 2009; 30:256-268.
41. Moskowitz SM, Silva SJ, Mayer-Hamblett N, et al., for the investigators and coordinators of the Epidemiologic Study of Cystic Fibrosis (ESCF). Shifting patterns of antibiotic use in cystic fibrosis. Pediatr Pulmnol 2008; 43:874-881.
42. Gibson RL, Retsch-Bogart GZ, Oermann C, et al. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr Pulmonol 2006; 41:656-665.
43. Coates AL, Green M, Leung K, et al. Rapid pulmonary delivery of inhaled tobramycin for Pseudomonas infection in cystic fibrosis: a pilot project. Pediatr Pulmonol 2008; 43:753-759.
44. Konstan MW, Geller DE, Minic P, et al. Effective treatment of chronic Pseudomonas aeruginosa (Pa) infection with tobramycin inhalation powder in cystic fibrosis patients. J Cyst Fibros 2009; 8:S27.
45. Retsch-Bogart GZ, Burns JL, Otto KL, et al., for the AZLI Phase II Study Group. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr Pulmonol 2008; 43:47-58.
46. Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine in cystic fibrosis. Chest 2009; 135:1223-1232.
47. McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine is effective in intensively-treated patients with cystic fibrosis. Am J Respir Crit Care Med 2008; 178:921-928.
48. Quittner AL, Modi AC, Wainwright C, et al. Determination of the minimally important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009; 135:1610-1618.
49. Study evaluating fosfomycin/tobramycin for inhalation in cystic fibrosis patients with Pseudomonas aeruginosa lung infection. http://clinicaltrials. gov/ct2/show/NCT00794586.
50. Wilson J, Moorehead L, Montgomery B. A phase 1 open label trial to assess the safety and tolerability of fosfomycin/tobramycin for inhalation (FTI) in subjects with cystic fibrosis (CF) or bronchiectasis (BE). Pediatr Pulmonol 2008; S31:320.
51. Santos RB, Prestidge CB, Brown ME, et al. Pharmacokinetics and pharmacodynamics of linezolid in children with cystic fibrosis. Pediatr Pulmonol 2009; 44:148-154.